FDA Expands Indication for Amivantamab in Lung Cancer ...Middle East

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after disease progression on or after an EGFR-TKI. Medscape Medical News

Hence then, the article about fda expands indication for amivantamab in lung cancer was published today ( Monday 23/09/2024 - 10:04 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Expands Indication for Amivantamab in Lung Cancer )

Also on site :

• Aussie World Cup Fan Goes Viral for Popeyes Review, Says Australia Is Missing Out
• Girl Boards Plane With Mystery Symptoms—Man Beside Her Changes Everything
• Walmart's 'Supportive' Sandals Are Just $15 During Its Summer Deals Event, and They Feel Like You're 'Walking on Air'